Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: A randomized phase III study

Lung Cancer

Volumn 34, Issue 1, 2001, Pages 1-13

  Jelić, Svetislav ^a   Mitrović, Labuda ^a   Radosavljević, Davorin ^a   Elezar, Elizabeta ^b   Babović, Nada ^a   Kovčin, Vladimir ^c   Tomašević, Zoran ^a   Kovačević, Svetlana ^d   Gavrilović, Dušica ^a   Radulović, Siniša ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^b Clinical Center 'Zemun'   (Yugoslavia)

^c University Hospital Center 'Bezanijska Kosa'

^d Clinical Centre 'Zvezdara'   (Yugoslavia)

Author keywords

Carboplatin; Cisplatin; Non small cell lung cancer; Phase III study

Indexed keywords

CARBOPLATIN; CISPLATIN; MITOMYCIN C; PLATINUM DERIVATIVE; POTASSIUM; SODIUM; VINDESINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; SUBSTITUTION THERAPY; SURVIVAL RATE; TOXICITY; TREATMENT OUTCOME;

EID: 0034845844     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(01)00239-2     Document Type: Article

References (27)

1. Combination chemotherapy with mitomycin, vindesine and cisplatin for non small cell lung cancer; association of antitumor activity with initial tumor burden and treatment center
2. Chemotherapy can prolong survival in patients with advanced non small cell lung cancer
3. Non small cell lung cancer collaborative group: Chemotherapy in non small cell lung cancer; a meta analysis using updated data on individual patients from 52 randomized clinical trials
4. Cisplatin plus vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules
5. Mitomycin, vindesine and cisplatin in the treatment of non small cell lung cancer: A pilot study of the Swiss group for clinical cancer research
6. Randomised prospective study of vindesine versus vindesine plus cisplatinum plus mitomycin C in advanced non small cell lung cancer
7. VP-16 and cisplatin in the treatment of non small cell lung cancer
8. Carboplatin versus cisplatin in solid tumors: An analysis of the literature
9. Combination chemotherapy in stage IV non small cell lung cancer; a study of the Eastern Cooperative Oncology Group
10. Reporting results of cancer treatment
11. Mitomycin C-vindesine-cisplatin versus mitomycin C-vindesine-carboplatin for advanced squamous cell bronchogenic carcinoma; an interim report, in Antypas G
12. 2 in combination with mitomycin C and vindesine; a randomized phase III study in 164 patients with stage IIIB and IV squamous cell bronchogenic carcinoma
13. Carboplatin: Current status and future prospects
14. A phase I and pharmakokinetic study of diamminecyclobutanedicarboxylatoplatinum (NSC 241240)
15. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II
16. Carboplatin and cisplatin: Are they equivalent in efficacy in 'optimal residual' advanced ovarian cancer?
17. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients A randomized phase II study
18. Randomised trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: A multiinstitutional study
19. A randomized trial of cisplatin etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with "good-risk" metastatic non-seminomatous germ cell tumors
20. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861
21. Docetaxel plus cisplatin versus docetaxel plus gemcitabine chemotherapy in advanced non small cell lung cancer: A preliminary analysis of a multicenter randomized phase II trial
22. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin
23. Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: A phase II trial of the Minnie Pearl Cancer Research Network
24. Phase II study of paclitaxel and carboplatin for advanced non-small-cell lung cancer
25. Is there any impact of new drugs on the outcome of advanced NSCLC? An overview of the Southern Italy Cooperative Oncology Group trials
26. Economic analysis of carboplatin versus cisplatin in lung and ovarian cancer